Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$10.84 - $16.55 $205,894 - $314,350
-18,994 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$15.69 - $21.14 $73,664 - $99,252
4,695 Added 32.83%
18,994 $298,000
Q3 2021

Nov 15, 2021

SELL
$15.35 - $21.27 $8,949 - $12,400
-583 Reduced 3.92%
14,299 $245,000
Q2 2021

Aug 16, 2021

BUY
$15.71 - $21.51 $73,271 - $100,322
4,664 Added 45.64%
14,882 $320,000
Q1 2021

May 17, 2021

SELL
$13.42 - $20.28 $51,519 - $77,854
-3,839 Reduced 27.31%
10,218 $153,000
Q4 2020

Feb 16, 2021

SELL
$9.77 - $13.81 $186,646 - $263,826
-19,104 Reduced 57.61%
14,057 $185,000
Q3 2020

Nov 16, 2020

SELL
$9.32 - $12.02 $441,479 - $569,375
-47,369 Reduced 58.82%
33,161 $320,000
Q2 2020

Aug 13, 2020

SELL
$9.66 - $12.02 $744,341 - $926,189
-77,054 Reduced 48.9%
80,530 $921,000
Q1 2020

May 15, 2020

SELL
$7.5 - $16.8 $27,060 - $60,614
-3,608 Reduced 2.24%
157,584 $1.63 Million
Q4 2019

Feb 14, 2020

SELL
$12.38 - $17.47 $17,604 - $24,842
-1,422 Reduced 0.87%
161,192 $2.65 Million
Q3 2019

Nov 14, 2019

BUY
$12.27 - $15.79 $1.56 Million - $2.01 Million
127,061 Added 357.38%
162,614 $2.16 Million
Q2 2019

Aug 14, 2019

SELL
$13.37 - $18.85 $116,706 - $164,541
-8,729 Reduced 19.71%
35,553 $501,000
Q1 2019

May 15, 2019

BUY
$17.59 - $31.05 $348,598 - $615,348
19,818 Added 81.01%
44,282 $815,000
Q4 2018

Feb 14, 2019

BUY
$18.97 - $31.47 $464,082 - $769,882
24,464 New
24,464 $639,000
Q4 2017

Feb 14, 2018

SELL
$12.85 - $18.1 $1.83 Million - $2.57 Million
-142,159 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$15.4 - $18.85 $2.19 Million - $2.68 Million
142,159
142,159 $2.55 Million

Others Institutions Holding VNDA

About Vanda Pharmaceuticals Inc.


  • Ticker VNDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,561,500
  • Market Cap $251M
  • Description
  • Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...
More about VNDA
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.